Perspective Therapeutics (CATX) Stock: Buy, Sell, or Hold?
CATX - Perspective Therapeutics, Inc.
$2.50
-0.02 (-0.79%)
▼
5d:
-15.82%
30d:
-21.38%
90d:
-29.58%
WAIT
LOW Confidence
Analysis Updated: Sep 28, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When CATX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CATX is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CATX is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CATX is currently trading at $2.50, which is considered oversold relative to its 30-day fair value range of $2.72 to $3.20.
Technical Outlook: Technically, CATX is in a downtrend. The price is currently testing key support at $2.44. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.29 (+391.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CATX is in a downtrend. The price is currently testing key support at $2.44. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.29 (+391.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.72 -
$3.20
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 391.4% below Wall St target ($12.29)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.72 -
$3.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.44
Resistance Level
$3.03
Current Trend
Downtrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.48
Wall Street Target
$12.29
(+391.4%)
Revenue Growth (YoY)
-72.1%
Share & Embed Analysis
Last updated: September 29, 2026 7:44 AM ET
Data refreshes hourly during market hours. Next update: 8:44 AM
Data refreshes hourly during market hours. Next update: 8:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CATX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 64 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 72 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 44 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 55 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 54 HOLD |
